2019 - Fellow of the American Association for the Advancement of Science (AAAS)
2008 - Fellow of the American Statistical Association (ASA)
His main research concerns Internal medicine, Cancer, Oncology, Cancer research and Pathology. His Internal medicine research includes elements of Gastroenterology, Surgery and Isotretinoin. His biological study spans a wide range of topics, including Prospective cohort study, Physical therapy, Immunology and Disease.
His work deals with themes such as Survival rate and Clinical endpoint, Clinical trial, Phases of clinical research, which intersect with Oncology. His Cancer research research integrates issues from Carcinogenesis, Gene, Mutation, Retinoic acid receptor and Receptor. His work deals with themes such as Sentinel lymph node, Head and neck cancer, Apoptosis and Cutaneous melanoma, which intersect with Pathology.
J. Jack Lee spends much of his time researching Internal medicine, Oncology, Cancer, Lung cancer and Cancer research. His Internal medicine research is multidisciplinary, relying on both Gastroenterology, Surgery and Pathology. His Oncology study combines topics from a wide range of disciplines, such as Head and neck squamous-cell carcinoma, Head and neck cancer, Phases of clinical research, Clinical endpoint and Biomarker.
His Cancer research incorporates themes from Radiation therapy, Proportional hazards model and Bioinformatics. His Lung cancer research is multidisciplinary, incorporating elements of Targeted therapy, KRAS, Lung and Adenocarcinoma. J. Jack Lee interconnects Carcinogenesis, Cancer cell, Mutation, Immunology and Receptor in the investigation of issues within Cancer research.
His primary areas of study are Internal medicine, Oncology, Cancer research, Clinical trial and Lung cancer. His Oncology study integrates concerns from other disciplines, such as Head and neck squamous-cell carcinoma, Carcinoma, Cohort and Immunotherapy. His research integrates issues of Immunohistochemistry, T cell, Immune system, Transcriptome and Adenocarcinoma in his study of Cancer research.
His Clinical trial research includes themes of MEDLINE, Randomized controlled trial, Bayesian probability, Artificial intelligence and Machine learning. The various areas that J. Jack Lee examines in his Lung cancer study include Cell, Ipilimumab, Genotype and Confidence interval. His research in Cancer intersects with topics in Placebo and Adverse effect.
J. Jack Lee mainly investigates Internal medicine, Oncology, Clinical trial, Lung cancer and Cancer. His work carried out in the field of Oncology brings together such families of science as Nivolumab, Immune checkpoint inhibitors, Immunotherapy and Cohort. He combines subjects such as Adverse effect, Randomized controlled trial, Drug development and Hazard ratio with his study of Clinical trial.
J. Jack Lee has included themes like Carcinoma, Lung and Immune system in his Lung cancer study. His studies deal with areas such as Survival rate and Gemcitabine as well as Carcinoma. His study in Immune system is interdisciplinary in nature, drawing from both Immunohistochemistry, Cancer research and Serology.
This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.
Comprehensive genomic characterization of head and neck squamous cell carcinomas
Michael S. Lawrence;Carrie Sougnez;Lee Lichtenstein;Kristian Cibulskis.
PROSTATE CANCER RADIATION DOSE RESPONSE: RESULTS OF THE M. D. ANDERSON PHASE III RANDOMIZED TRIAL
Alan Pollack;Gunar K Zagars;George Starkschall;John A Antolak.
International Journal of Radiation Oncology Biology Physics (2002)
Exosomes facilitate therapeutic targeting of oncogenic KRAS in pancreatic cancer
Sushrut Kamerkar;Valerie S. LeBleu;Hikaru Sugimoto;Sujuan Yang.
Multi-institutional melanoma lymphatic mapping experience: the prognostic value of sentinel lymph node status in 612 stage I or II melanoma patients.
Jeffrey E. Gershenwald;William Thompson;Paul F. Mansfield;Jeffrey E. Lee.
Journal of Clinical Oncology (1999)
An Epithelial–Mesenchymal Transition Gene Signature Predicts Resistance to EGFR and PI3K Inhibitors and Identifies Axl as a Therapeutic Target for Overcoming EGFR Inhibitor Resistance
Lauren Averett Byers;Lixia Diao;Jing Wang;Pierre Saintigny.
Clinical Cancer Research (2013)
Retrovirus-mediated wild-type p53 gene transfer to tumors of patients with lung cancer.
J. A. Roth;D. Nguyen;D. D. Lawrence;B. L. Kemp.
Nature Medicine (1996)
bcl-2 and p53 Oncoprotein Expression during Colorectal Tumorigenesis
F. A. Sinicrope;San Bao Ruan;K. R. Cleary;L. C. Stephens.
Cancer Research (1995)
The BATTLE Trial: Personalizing Therapy for Lung Cancer
Edward S. Kim;Roy S. Herbst;Ignacio Ivan Wistuba;Jiun-Kae Jack Lee.
Cancer Discovery (2011)
Local consolidative therapy versus maintenance therapy or observation for patients with oligometastatic non-small-cell lung cancer without progression after first-line systemic therapy: a multicentre, randomised, controlled, phase 2 study
Daniel R Gomez;George R Blumenschein;J Jack Lee;Mike Hernandez.
Lancet Oncology (2016)
Intratumor heterogeneity in localized lung adenocarcinomas delineated by multiregion sequencing
Jianjun Zhang;Junya Fujimoto;Jianhua Zhang;David C. Wedge.
If you think any of the details on this page are incorrect, let us know.
We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below: